•  
  •  
  •  
  •  

2026-08-09 15:57:35

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore

Keywords Selected:  USA

Research

  • 45% of Newbie traders claim that 'not knowing enough' is the primary reason for losses incurred in Futures & Options trading - Sharekhan's survey reveals
  • Domestic primary aluminium manufacturing entities are behind the curve in the transition to a greener future: ICRA
  • Campus Activewear - IPO - Strong Business Model, but Valuation is Stretched

Stock Report

  • Lupin Announces the Approval of Diazepam Injection, USP in the United States
  • Elgi Compressors USA Inc receives tariff refund of $2.68 Mn
  • Susan Electricals India Ltd reports 2.5x growth in Q1FY27 performance
  • PDS Limited and Busana Apparel Group announce Strategic Partnership to Build the Next Generation of Global Apparel Manufacturing
  • 3i Infotech Inc., USA receives order worth Rs. 1.47 crore
  • Blue Cloud Softech Solutions Ltd - USA Executes Five-Year Master Services Agreement for AI Services with SpaceX International Ltd, MY
  • Glenmark Pharmaceuticals Inc., USA launches Olanzapine for Injection, 10 mg/vial, Single-Dose Vial
  • Aurobindo Pharma USA Inc completes acquisition of Lannett Company, Inc
  • Waaree Energies' Clarifies U.S. Customs Determination
  • Lupin Launches Azilsartan Medoxomil Tablets in the United States
  • Glenmark Pharmaceuticals Inc., USA launches Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial
  • Welspun USA Inc commences commercial production of Pillow Manufacturing unit
  • Campus Activewear Limited announces Q4 & FY26 performance
  • Sunita Defense Inc, USA has established its full time office in Chicago USA
  • Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin® HFA
  • Carysil Limited Announces 25% Expansion in Quartz Sink Capacity for US Retail Giants
  • Lupin Pharmaceuticals, Inc, USA enters into settlement agreement with Humana Inc
  • Unichem Pharmaceuticals (USA) Issues Voluntary Recall of Buspirone Hydrochloride Tablets
  • 3i Infotech Inc., USA receives order worth Rs. 2.76 crores
  • 3i Infotech Inc., USA receives order worth approx. Rs. 1.63 crores
  • Glenmark Pharmaceuticals announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS® in the U.S.
  • Glenmark Therapeutics Inc., USA launches Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)
  • Sunita Tools Ltd forms Wholly Owned Subsidiary, Sunita Defence Inc, in Wyoming, USA
  • 3i Infotech Inc., USA receives order worth Rs. 2.21 crores

Industry News

  • LiaPlus AI raises INR 2 Crore in Seed Round led by Inflection Point Ventures

Latest Post

  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025